NOW RECRUITING: Iovance is conducting a Phase 2 clinical trial to assess the safety, efficacy and feasibility of an adoptive cell therapy based on autologous TIL (LN-144-01), followed by IL-2, in the treatment of patients with refractory metastatic melanoma. The multi-center, single-arm trial is now recruiting patients at various sites in the US.
Key eligibility criteria:
• Measurable metastatic melanoma and ≥ 1 lesion resectable for TIL generation
• At least one prior systemic therapy
• Age ≥ 18
• ECOG PS 0-1
• Primary: Safety
• Secondary: Efficacy defined as ORR, CRR, PFS, DOR and OS